These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 25721150)

  • 21. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
    Yadlapati A; Groh C; Passman R
    Am J Cardiol; 2014 Apr; 113(8):1362-3. PubMed ID: 24576547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.
    Escobar C; Martí-Almor J; Pérez Cabeza A; Martínez-Zapata MJ
    Rev Esp Cardiol (Engl Ed); 2019 Apr; 72(4):305-316. PubMed ID: 29606361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
    Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
    J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
    Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K
    J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale.
    Xian Y; Hernandez AF; Harding T; Fonarow GC; Bhatt DL; Suter RE; Khan Y; Schwamm LH; Peterson ED
    Am Heart J; 2016 Dec; 182():28-35. PubMed ID: 27914497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
    Tepper PG; Mardekian J; Masseria C; Phatak H; Kamble S; Abdulsattar Y; Petkun W; Lip GYH
    PLoS One; 2018; 13(11):e0205989. PubMed ID: 30383768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
    Wu S; Yang YM; Zhu J; Wan HB; Wang J; Zhang H; Shao XH
    Am J Cardiol; 2016 Mar; 117(6):926-34. PubMed ID: 26803384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing.
    Cho MS; Yun JE; Park JJ; Kim YJ; Lee J; Kim H; Park DW; Nam GB
    Am J Cardiol; 2020 May; 125(9):1332-1338. PubMed ID: 32098658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2018 Jul; 122(1):69-75. PubMed ID: 29681367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmaco-utilization and outcomes in patients treated with oral anticoagulants from 2014 to 2015: evidences from administrative databases of the Romagna Local Health Unit].
    Degli Esposti L; Perrone V; Saragoni S; Buda S; Piovaccari G
    G Ital Cardiol (Rome); 2020 Jan; 21(1):25-33. PubMed ID: 31960832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation.
    Hansen PS; Sanchez R; Walfridsson H
    Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation.
    Brais C; Larochelle J; Turgeon MH; Blais L; Farand P; Perreault S; Letemplier G; Beauchesne MF
    J Pharm Pharm Sci; 2017; 20():8-14. PubMed ID: 28459661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel oral anticoagulants for atrial fibrillation.
    How CH
    Singapore Med J; 2015 Dec; 56(12):657-8; quiz 659. PubMed ID: 26702159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
    Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB;
    Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project.
    Li WH; Huang D; Chiang CE; Lau CP; Tse HF; Chan EW; Wong ICK; Lip GYH; Chan PH; Siu CW
    Clin Cardiol; 2017 Apr; 40(4):222-229. PubMed ID: 27893153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
    Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.